These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 18025877

  • 1. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
    Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.
    AIDS; 2007 Nov 30; 21(18):2409-15. PubMed ID: 18025877
    [Abstract] [Full Text] [Related]

  • 2. Reduced lopinavir exposure during pregnancy.
    Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.
    AIDS; 2006 Oct 03; 20(15):1931-9. PubMed ID: 16988514
    [Abstract] [Full Text] [Related]

  • 3. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A.
    J Antimicrob Chemother; 2008 Sep 03; 62(3):579-82. PubMed ID: 18477709
    [Abstract] [Full Text] [Related]

  • 4. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.
    Antivir Ther; 2006 Sep 03; 11(4):421-9. PubMed ID: 16856615
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.
    Antivir Ther; 2007 Sep 03; 12(5):825-30. PubMed ID: 17713166
    [Abstract] [Full Text] [Related]

  • 7. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.
    Ther Drug Monit; 2007 Oct 03; 29(5):648-51. PubMed ID: 17898658
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
    Martinez-Rebollar M, Lonca M, Perez I, Soy D, Brunet M, Martin R, Coll O, Hernandez S, Laguno M, Milinkovic A, Larrousse M, Calvo M, Blanco JL, Martínez E, Gatell JM, Mallolas J.
    Ther Drug Monit; 2011 Dec 03; 33(6):772-7. PubMed ID: 22105596
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G.
    Antivir Ther; 2008 Dec 03; 13(7):901-7. PubMed ID: 19043924
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Moltó J, Deig E, Valle M, Maria Llibre J, Miranda C, Cedeño S, Valero S, Negredo E, Clotet B.
    Ther Drug Monit; 2010 Feb 03; 32(1):93-6. PubMed ID: 20040897
    [Abstract] [Full Text] [Related]

  • 12. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.
    HIV Med; 2011 Oct 03; 12(9):570-9. PubMed ID: 21569187
    [Abstract] [Full Text] [Related]

  • 13. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.
    AIDS; 2006 May 12; 20(8):1131-9. PubMed ID: 16691064
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
    von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A.
    Antivir Ther; 2008 May 12; 13(8):1039-46. PubMed ID: 19195329
    [Abstract] [Full Text] [Related]

  • 15. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
    Winston A, Bloch M, Carr A, Amin J, Mallon PW, Ray J, Marriott D, Cooper DA, Emery S.
    J Antimicrob Chemother; 2005 Aug 12; 56(2):380-7. PubMed ID: 15996972
    [Abstract] [Full Text] [Related]

  • 16. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
    Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, Friese K, Grubert TA.
    AIDS; 2006 Aug 22; 20(13):1737-43. PubMed ID: 16931938
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
    Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, Barassi A, Maserati R, Sighinolfi L, D'Arminio Monforte A, Melzi D'Eril GV.
    Ther Drug Monit; 2011 Jun 22; 33(3):303-8. PubMed ID: 21544015
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.
    J Antimicrob Chemother; 2008 Jan 22; 61(1):200-5. PubMed ID: 17999977
    [Abstract] [Full Text] [Related]

  • 20. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS, IMPAACT 1026s Study Team.
    J Acquir Immune Defic Syndr; 2011 Apr 15; 56(5):412-9. PubMed ID: 21283017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.